HGF and gastroesophageal junction adenocarcinoma: In a randomized placebo-controlled phase II study, the efficacy of the anti-HGF antibody rilotumumab was evaluated in combination with platinum-based chemotherapy as first-line treatment in patients with advanced gastric or GEJ adenocarcinoma [45].